Back to News
Market Impact: 0.25
Attovia Therapeutics Reports Sustained Itch Relief in Small Study, Plans Phase 2 Trials
Source: marketbeat.com
Healthcare & BiotechCompany Fundamentals
Attovia Therapeutics reported 12-week results from a small Phase 1b study of experimental itch treatment ATTO-1310. The company said a single dose produced sustained responses in patients with chronic pruritus of unknown origin and high-itch atopic dermatitis; the article provides no response rates or other numerical efficacy data.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
More News
- Elon Musk once said the Cybertruck would be Tesla’s ‘best product ever.’ Now he’s winding down production
- Fox completes its $22B acquisition of Roku
- Elanco Shares Jump After Q3 Beat and Outlook Raise
- Paraguay’s Santiago Pena under arrest, new president Pedro Alliana sworn in
- FIGS Beats Earnings as Demand Outstrips Supply, CEO Trina Spear Says
- OpenAI valued at $1.25 trillion, as rival Anthropic nears its IPO